BioCryst to Report Second Quarter 2022 Financial Results on August 4
BioCryst Pharmaceuticals, Inc. (BCRX) will announce its second quarter 2022 financial results on August 4, 2022, followed by a conference call at 8:30 a.m. ET for a corporate update. The live call can be accessed at 866-374-5140 (domestic) or 404-400-0571 (international) using conference ID 68509725#. A webcast and slides will be available on the company's investor website, with a replay accessible afterward.
BioCryst focuses on developing oral treatments for rare diseases, including ORLADEYO (berotralstat) and other pipeline candidates.
- Upcoming second quarter financial results on August 4, 2022 could lead to increased investor interest.
- Continued development of oral treatments for rare diseases enhances BioCryst's market position.
- None.
RESEARCH TRIANGLE PARK, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its second quarter 2022 financial results Thursday, August 4, 2022.
BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.
The live call may be accessed by dialing 866-374-5140 for domestic callers and 404-400-0571 for international callers and using conference ID 68509725#. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A replay of the call will be available on the company website.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO® (berotralstat) is approved in the United States and multiple global markets. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and yellow fever. RAPIVAB® (peramivir injection) is approved in the U.S. and multiple global markets, with post-marketing commitments ongoing. For more information, please visit the company’s website at www.biocryst.com.
BCRXW
Contact:
Investors
John Bluth
+1 919 859 7910
jbluth@biocryst.com
Media
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com
FAQ
When will BioCryst Pharmaceuticals report its second quarter 2022 financial results?
What time is the BioCryst Pharmaceuticals second quarter 2022 conference call?
How can I access the BioCryst Pharmaceuticals conference call for Q2 2022?
What does BioCryst Pharmaceuticals focus on in terms of drug development?
